01 2Ebixa
02 2Memary
03 3Namenda
04 4Namenda XR
05 2Namzaric
Main Therapeutic Indication : Alzheimer Disease
Currency : USD
2017 Revenue in Millions : 453
2016 Revenue in Millions : 628
Growth (%) : -28
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 71
2017 Revenue in Millions : 453
Growth (%) : -84%
Main Therapeutic Indication : Alzheimer Diseases
Currency : USD
2016 Revenue in Millions : 628
2015 Revenue in Millions : 759
Growth (%) : -17
Main Therapeutic Indication : Alzheimer Disease
Currency : USD
2017 Revenue in Millions : 0.1
2016 Revenue in Millions : 15
Growth (%) : -99
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 89
2018 Revenue in Millions : 116
Growth (%) : -23
Memantine And Donepezil Hydrochloride
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 58
2015 Revenue in Millions : 11
Growth (%) : 427
Main Therapeutic Indication : Alzheimer Diseases
Currency : USD
2016 Revenue in Millions : 15
2015 Revenue in Millions : 556
Growth (%) : -97
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 23
2018 Revenue in Millions : 71
Growth (%) : -68
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 249
2019 Revenue in Millions : 465
Growth (%) : -46
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 473
2018 Revenue in Millions : 465
Growth (%) : 2
LOOKING FOR A SUPPLIER?